When was Marengo founded?

Marengo was founded in 2015 and raised its 1st funding round 6 years after it was founded.

Where is Marengo located?

Marengo is headquartered in Cambridge, United States.

How many employees does Marengo have?

As of Jun 30, 2026, the latest employee count at Marengo is 41.

Is Marengo a funded company?

Marengo is a funded company, having raised a total of $***** in its 1st and only funding round, a Series C round on Nov 08, 2021.

When was the latest funding round of Marengo?

Marengo's latest funding was a $***** Series C round on Nov 08, 2021, with participation from 1 investor. Its primary sector is Cell Therapy. In United States, the Cell Therapy sector has seen $948M in funding in 2026 to date.

Where does Marengo rank among its competitors?

Marengo ranks 665th amongst 3372 active competitors, of which 1145 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Marengo?

Marengo's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Marengo - 2026 Company Profile, Team, Funding & Competitors

Marengo is a series C company based in Cambridge (United States), founded in 2015. It operates as a Developer of cell therapy for the treatment of cancer. Marengo has raised $80M in funding from Apple Tree Partners. The company has 3372 active competitors, including 1145 funded and 803 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of cell therapy for the treatment of cancer. The lead program STAR0602 is an antibody fusion molecule that binds and activates specific T cells to fight tumors by directly targeting Vβ TCR variants to enhance anti-tumor activity. Also, includes STAR0615, STAR2002, SKAR3012, and STAR0602X for solid tumors.

Website: marengotx.com
Social
Email ID: *****@marengotx.com
Phone Number: +1 **********

Key Metrics

Founded Year

2015

Location

Cambridge, United States

Stage

Series C

Total Funding

$80M in 1 round

Latest Funding Round

Series C, Nov 08, 2021, $*****

Investors

Apple Tree Partners

Ranked

665^th among 3372 active competitors

Employee Count

41 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3159 more

View Marengo's full profile

Marengo has raised a total funding of $80M over 1 round. Its latest funding round was a Series C round on Nov 08, 2021 for $*****. 1 investor participated in its latest round. Marengo has 1 institutional investor.

Here is the list of recent funding rounds of Marengo:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 08, 2021	3682047	Series C	5637258	4192498	2426746	4925415

Access funding benchmarks and valuations. Sign up today!

View details of Marengo's funding rounds and investors

Marengo's employee count trend

Marengo has 41 employees as of Jun 26. Here is Marengo's employee count trend over the years:

Uncover Marengo's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Marengo include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Marengo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
665th	Marengo 2015, Cambridge (United States), Series C	Developer of cell therapy for the treatment of cancer	$80M	Apple Tree Partners	49/100